[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 38
1. Marais E, Mlambo CK, Lewis JJ, Rastogi N, Zozio T, Grobusch MP, Duse A, Victor T, Warren RW: Treatment outcomes of multidrug-resistant tuberculosis patients in Gauteng, South Africa. Infection; 2014 Apr;42(2):405-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Univariable and multivariable analysis (P = 0.05) identified the year of MDR-TB diagnosis and spoligotype-defined families as factors associated with treatment outcome.
  • Molecular typing of the strains revealed a diverse group of spoligotypes, with Beijing, LAM4 and H3 making up the largest groups.

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Tuberc Lung Dis. 2010 Apr;14(4):413-9 [20202298.001]
  • [Cites] Int J Tuberc Lung Dis. 2009 Jul;13(7):855-61 [19555535.001]
  • [Cites] Int J Tuberc Lung Dis. 2013 Aug;17(8):1043-8 [23827028.001]
  • [Cites] PLoS One. 2011;6(7):e20436 [21799728.001]
  • [Cites] PLoS One. 2011;6(8):e23081 [21886778.001]
  • [Cites] Int J Tuberc Lung Dis. 2005 Jun;9(6):640-5 [15971391.001]
  • [Cites] Int J Tuberc Lung Dis. 2004 May;8(5):560-7 [15137531.001]
  • [Cites] BMC Health Serv Res. 2013 Jul 09;13:268 [23837531.001]
  • [Cites] PLoS One. 2013;8(1):e54587 [23349933.001]
  • [Cites] Eur Respir J. 1998 Aug;12(2):505-10 [9727811.001]
  • [Cites] Emerg Infect Dis. 2006 Apr;12(4):687-8 [16704823.001]
  • [Cites] Lancet Infect Dis. 2009 Mar;9(3):153-61 [19246019.001]
  • [Cites] Int J Tuberc Lung Dis. 2012 Jan;16(1):90-7 [22236852.001]
  • [Cites] Lancet. 2010 May 22;375(9728):1798-807 [20488525.001]
  • [Cites] Scand J Infect Dis. 2010 Apr;42(4):288-93 [20082573.001]
  • [Cites] Int J Tuberc Lung Dis. 2008 Oct;12(10):1182-9 [18812049.001]
  • [Cites] J Clin Microbiol. 2012 Sep;50(9):2857-62 [22649019.001]
  • [Cites] Eur Respir J. 2009 May;33(5):1085-94 [19164345.001]
  • [Cites] JAMA. 2000 May 17;283(19):2537-45 [10815117.001]
  • [Cites] J Infect Dis. 2004 Nov 1;190(9):1670-6 [15478074.001]
  • [Cites] Lancet. 2006 Nov 4;368(9547):1575-80 [17084757.001]
  • [Cites] J Clin Microbiol. 2013 Jun;51(6):1818-25 [23554196.001]
  • [Cites] Int J Tuberc Lung Dis. 2012 Aug;16(8):998-1004 [22668560.001]
  • [Cites] Int J Tuberc Lung Dis. 2005 May;9(5):507-13 [15875921.001]
  • [Cites] PLoS Med. 2012;9(8):e1001300 [22952439.001]
  • [Cites] Int J Tuberc Lung Dis. 2006 Jun;10(6):649-55 [16776452.001]
  • [Cites] JAMA. 2007 Jan 24;297(4):380-6 [17244834.001]
  • [Cites] Int J Tuberc Lung Dis. 2010 Apr;14(4):420-6 [20202299.001]
  • [Cites] Int J Tuberc Lung Dis. 2008 Aug;12(8):978-80 [18647461.001]
  • [Cites] PLoS One. 2013;8(3):e58664 [23516529.001]
  • [Cites] J Clin Microbiol. 2012 Mar;50(3):995-1002 [22170931.001]
  • [Cites] Emerg Infect Dis. 2008 Nov;14(11):1700-6 [18976552.001]
  • [Cites] PLoS One. 2012;7(10):e46943 [23115633.001]
  • [Cites] Int J Tuberc Lung Dis. 2013 Apr;17(4):520-5 [23485386.001]
  • (PMID = 24363208.001).
  • [ISSN] 1439-0973
  • [Journal-full-title] Infection
  • [ISO-abbreviation] Infection
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MR/K007467/1; United Kingdom / Medical Research Council / / MR/K012126/1; United States / PHS HHS / / 1U2RTW007370/3
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


2. Sato Y, Koyama S, Kuwashima S, Kato M, Okuya M, Fukushima K, Kurosawa H, Arisaka O: Central hypothyroidism in a pediatric case of primary acute monoblastic leukemia with central nervous system infiltration: A case report. Medicine (Baltimore); 2017 Jun;96(26):e7329
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central hypothyroidism in a pediatric case of primary acute monoblastic leukemia with central nervous system infiltration: A case report.
  • RATIONALE: Central nervous system (CNS) leukemia is a frequent diagnosis in pediatric acute myeloblastic leukemia (AML) and includes neural symptoms.
  • However, CNS leukemia is rarely associated with central hypsothyroidism.
  • PATIENT CONCERNS AND DIAGNOSES: A 2-year-old female with AML with MLL rearrangement presented with CNS infiltration.
  • The FT4 concentration increased after levothyroxine treatment, but later decreased after relapse of CNS leukemia.
  • After remission of CNS leukemia, the TSH and FT4 concentrations quickly recovered to their normal ranges.
  • LESSONS: We believe that the CNS leukemia directly affected TSH and thyroid hormone secretion in our patient.
  • [MeSH-major] Central Nervous System Neoplasms / complications. Central Nervous System Neoplasms / secretion. Hypothyroidism / complications. Leukemia, Monocytic, Acute / complications. Leukemia, Monocytic, Acute / pathology
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Female. Humans. Thyrotropin / blood

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pediatr Hematol Oncol. 1990 Fall;12(3):325-30 [2240480.001]
  • [Cites] Pediatr Blood Cancer. 2017 Jan;64(1):64-70 [27555087.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):486-8 [11054681.001]
  • [Cites] J Clin Res Pediatr Endocrinol. 2014 Sep;6(3):144-51 [25241607.001]
  • [Cites] Pediatr Int. 2004 Jun;46(3):291-5 [15151545.001]
  • [Cites] Pediatr Blood Cancer. 2012 Apr;58(4):519-24 [21618422.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3273-9 [10986060.001]
  • [Cites] Br J Haematol. 1985 Sep;61(1):135-8 [3863666.001]
  • [Cites] Pediatr Blood Cancer. 2013 Jan;60(1):110-5 [22628201.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):393-8 [16550530.001]
  • [Cites] Pediatr Blood Cancer. 2010 Sep;55(3):414-20 [20658610.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9172-8 [16361619.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(10):991-5 [15806126.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Dec;84(12):4472-9 [10599705.001]
  • [Cites] J Endocrinol Invest. 1988 Jan;11(1):43-5 [3162927.001]
  • [Cites] Blood. 2011 Oct 6;118(14):3785-93 [21795742.001]
  • (PMID = 28658145.001).
  • [ISSN] 1536-5964
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin
  •  go-up   go-down


3. Hussain S, Adil SN: Rare cytogenetic abnormalities in acute myeloid leukemia transformed from Fanconi anemia - a case report. BMC Res Notes; 2013;6:316
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare cytogenetic abnormalities in acute myeloid leukemia transformed from Fanconi anemia - a case report.
  • BACKGROUND: Fanconi's anemia (FA) is an inherited bone marrow failure syndrome that carries a higher risk of transformation to acute myeloid leukemia (AML) when compared with general population.
  • AML is the initial presentation in approximately one third of patients.
  • These findings were consistent with acute myelomonocytic leukemia.
  • CONCLUSION: The recognition of specific cytogenetic abnormalities present in FA known to predispose to AML is crucial for early haematopoietic stem cell transplant (HSCT) before transformation to leukemia.
  • [MeSH-major] Fanconi Anemia / genetics. Leukemia, Myeloid, Acute / genetics


Advertisement
4. Jensen HA, Styskal LE, Tasseff R, Bunaciu RP, Congleton J, Varner JD, Yen A: The Src-family kinase inhibitor PP2 rescues inducible differentiation events in emergent retinoic acid-resistant myeloblastic leukemia cells. PLoS One; 2013;8(3):e58621
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Src-family kinase inhibitor PP2 rescues inducible differentiation events in emergent retinoic acid-resistant myeloblastic leukemia cells.
  • Retinoic acid is an embryonic morphogen and dietary factor that demonstrates chemotherapeutic efficacy in inducing maturation in leukemia cells.
  • Using HL60 model human myeloid leukemia cells, where all-trans retinoic acid (RA) induces granulocytic differentiation, we developed two emergent RA-resistant HL60 cell lines which are characterized by loss of RA-inducible G1/G0 arrest, CD11b expression, inducible oxidative metabolism and p47(phox) expression.
  • Other signaling events that define the wild-type (WT) response are compromised, including c-Raf phosphorylation and increased expression of c-Cbl, Vav1, and the Src-family kinases (SFKs) Lyn and Fgr.

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2009 Sep 18;284(38):25664-77 [19635790.001]
  • [Cites] Exp Cell Res. 2009 Aug 1;315(13):2241-8 [19298812.001]
  • [Cites] Leukemia. 2010 Mar;24(3):663-5 [20033056.001]
  • [Cites] Exp Cell Res. 2010 Oct 1;316(16):2692-706 [20570673.001]
  • [Cites] Adv Drug Deliv Rev. 2010 Oct 30;62(13):1285-98 [20654663.001]
  • [Cites] Annu Rev Pathol. 2011;6:345-64 [21073338.001]
  • [Cites] Leukemia. 2012 Jun;26(6):1180-8 [22182854.001]
  • [Cites] EMBO J. 2001 Apr 17;20(8):1940-51 [11296227.001]
  • [Cites] Redox Rep. 2001;6(1):27-36 [11333112.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7783-8 [11427728.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):7913-9 [11756411.001]
  • [Cites] J Clin Invest. 2002 Jun;109(12):1561-9 [12070303.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):11221-6 [12551923.001]
  • [Cites] Cell Signal. 2004 Apr;16(4):423-33 [14709332.001]
  • [Cites] J Exp Med. 1979 Apr 1;149(4):969-74 [219131.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 May;77(5):2936-40 [6930676.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Jun;78(6):3863-6 [6943586.001]
  • [Cites] Cancer Res. 1987 Jan 1;47(1):129-34 [3466687.001]
  • [Cites] Blood. 1987 Nov;70(5):1233-44 [3311197.001]
  • [Cites] Br J Cancer Suppl. 1988 Dec;9:41-5 [3076064.001]
  • [Cites] Mol Cell Biol. 1990 Dec;10(12):6445-53 [2174108.001]
  • [Cites] J Immunol. 1991 Jan 15;146(2):701-7 [1987282.001]
  • [Cites] FASEB J. 1991 Nov;5(14):2924-33 [1661245.001]
  • [Cites] Blood. 1992 Oct 15;80(8):1885-9 [1327285.001]
  • [Cites] J Biol Chem. 1993 Aug 15;268(23):17309-16 [8349614.001]
  • [Cites] Haematologica. 1995 Mar-Apr;80(2):161-75 [7628754.001]
  • [Cites] J Biol Chem. 1996 Jan 12;271(2):695-701 [8557675.001]
  • [Cites] Leuk Res. 1996 Sep;20(9):761-9 [8947586.001]
  • [Cites] Blood. 1997 May 15;89(10):3607-14 [9160665.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4282-9 [9192750.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3163-72 [9679985.001]
  • [Cites] Leukemia. 1999 Jun;13(6):855-61 [10360372.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48692-701 [15356004.001]
  • [Cites] Mol Cell. 2005 Jan 21;17(2):215-24 [15664191.001]
  • [Cites] J Biol Chem. 2005 Feb 25;280(8):6872-8 [15591313.001]
  • [Cites] Exp Cell Res. 2005 May 15;306(1):56-63 [15878332.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Dec;56(6):585-93 [16012865.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Nov;6(11):827-37 [16227978.001]
  • [Cites] Eur J Cell Biol. 2006 Feb;85(2):117-32 [16439309.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 10;341(2):363-8 [16414009.001]
  • [Cites] Mol Biol Cell. 2006 Mar;17(3):1141-53 [16407412.001]
  • [Cites] J Cell Biochem. 2006 Apr 15;97(6):1328-38 [16329108.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Nov 17;350(2):450-6 [17010316.001]
  • [Cites] Cell Cycle. 2007 Jan 1;6(1):3-7 [17218791.001]
  • [Cites] Biochim Biophys Acta. 2007 Aug;1773(8):1263-84 [17126425.001]
  • [Cites] Biochem J. 2007 Dec 15;408(3):297-315 [17850214.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3081-90 [18065491.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2269-79 [18056483.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):4375-86 [18006504.001]
  • [Cites] FASEB J. 2008 May;22(5):1560-71 [18171692.001]
  • [Cites] Mol Cell. 2008 Sep 26;31(6):862-72 [18922468.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8761-9 [18974118.001]
  • [Cites] Exp Cell Res. 2010 Jan 1;316(1):38-47 [19747912.001]
  • (PMID = 23554907.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA033505; United States / NCI NIH HHS / CA / CA152870
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AG 1879; 0 / Antigens, CD11b; 0 / Antineoplastic Agents; 0 / ITGAM protein, human; 0 / Membrane Glycoproteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-vav; 0 / Pyrimidines; 0 / VAV1 protein, human; 5688UTC01R / Tretinoin; EC 1.6.3.1 / NADPH Oxidase; EC 1.6.3.1 / neutrophil cytosolic factor 1; EC 2.7.10.2 / lyn protein-tyrosine kinase; EC 2.7.10.2 / proto-oncogene proteins c-fgr; EC 2.7.10.2 / src-Family Kinases; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human; EC 6.3.2.- / CBL protein, human; EC 6.3.2.- / Proto-Oncogene Proteins c-cbl
  • [Other-IDs] NLM/ PMC3598855
  •  go-up   go-down


5. Bunaciu RP, Yen A: 6-Formylindolo (3,2-b)carbazole (FICZ) enhances retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells. Mol Cancer; 2013;12:39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 6-Formylindolo (3,2-b)carbazole (FICZ) enhances retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells.
  • We recently reported that AhR promotes retinoic acid (RA)-induced granulocytic differentiation of HL-60 myeloblastic leukemia cells by restricting the nuclear abundance of the stem cell associated transcription factor Oct4.
  • The standard clinical management of acute promyelocytic leukemia (APL) is differentiation induction therapy using RA.
  • But RA is not effective for other myeloid leukemias, making the mechanism of RA-induced differentiation observed in a non-APL myeloid leukemia of interest.
  • To our knowledge, this is the first study regarding the influence of FICZ on RA-induced differentiation in any type of leukemic blasts.
  • METHODS: Using flow cytometry and Western blotting assays, we determined the effects of FICZ on RA-induced differentiation of HL-60 human leukemia cells.
  • [MeSH-major] Carbazoles / pharmacology. Cell Differentiation / drug effects. Leukemia, Promyelocytic, Acute / metabolism. Leukemia, Promyelocytic, Acute / pathology. Tretinoin / pharmacology

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2008 Sep;7(9):3729-36 [18642942.001]
  • [Cites] FEBS Lett. 2008 Jul 23;582(17):2508-14 [18571505.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8761-9 [18974118.001]
  • [Cites] Free Radic Biol Med. 2009 Sep 15;47(6):825-34 [19559082.001]
  • [Cites] J Biol Chem. 2009 Sep 18;284(38):25664-77 [19635790.001]
  • [Cites] Cancer Res. 2010 Jan 1;70(1):212-20 [19996281.001]
  • [Cites] Mol Endocrinol. 2010 Feb;24(2):359-69 [20032195.001]
  • [Cites] Arch Biochem Biophys. 2010 Sep 1;501(1):134-41 [20450880.001]
  • [Cites] Science. 2010 Sep 10;329(5997):1345-8 [20688981.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Nov 30;107(48):20597-8 [21084638.001]
  • [Cites] Cancer Res. 2011 Mar 15;71(6):2371-80 [21262915.001]
  • [Cites] Leuk Lymphoma. 2011 Dec;52(12):2372-9 [21740303.001]
  • [Cites] Leukemia. 2012 Jun;26(6):1180-8 [22182854.001]
  • [Cites] Leuk Lymphoma. 2012 Sep;53(9):1779-84 [22356114.001]
  • [Cites] Biol Chem. 2013 Jun;394(6):729-39 [23370907.001]
  • [Cites] Carcinogenesis. 2013 Jul;34(7):1620-7 [23455376.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1999 Oct;35(9):527-32 [10548434.001]
  • [Cites] Arch Biochem Biophys. 2000 Jan 1;373(1):163-74 [10620335.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2000 Apr;36(4):249-55 [10852350.001]
  • [Cites] Gene Expr. 1999;8(5-6):273-86 [10947077.001]
  • [Cites] Curr Drug Metab. 2001 Jun;2(2):149-64 [11469723.001]
  • [Cites] Toxicol Appl Pharmacol. 2002 Jun 1;181(2):116-23 [12051995.001]
  • [Cites] J Biol Chem. 2002 Jun 28;277(26):23949-57 [11971897.001]
  • [Cites] Am J Ind Med. 2002 Dec;42(6):474-80 [12439870.001]
  • [Cites] J Nutr. 2003 Jan;133(1):277S-281S [12514309.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32544-51 [12805378.001]
  • [Cites] Zoolog Sci. 2004 May;21(5):541-51 [15170058.001]
  • [Cites] Am J Pathol. 1972 Mar;66(3):589-92 [4551297.001]
  • [Cites] New Biol. 1991 Dec;3(12):1206-19 [1667479.001]
  • [Cites] Mol Cell Biol. 1992 Oct;12(10):4666-76 [1328857.001]
  • [Cites] Mol Pharmacol. 1992 Oct;42(4):603-12 [1331752.001]
  • [Cites] Blood. 1996 Jan 1;87(1):227-37 [8547646.001]
  • [Cites] Cell. 1996 May 3;85(3):403-14 [8616895.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11557-62 [8626717.001]
  • [Cites] Biochem Pharmacol. 1996 Nov 22;52(10):1599-612 [8937476.001]
  • [Cites] Genes Cells. 1997 Oct;2(10):645-54 [9427285.001]
  • [Cites] Biochemistry. 1998 Feb 3;37(5):1438-46 [9477973.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3163-72 [9679985.001]
  • [Cites] Cell. 1998 Oct 30;95(3):379-91 [9814708.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Dec 18;253(2):346-51 [9878540.001]
  • [Cites] FEBS Lett. 2005 Jan 17;579(2):464-8 [15642359.001]
  • [Cites] Mol Cell. 2005 Jan 21;17(2):215-24 [15664191.001]
  • [Cites] J Biol Chem. 2005 Feb 25;280(8):6872-8 [15591313.001]
  • [Cites] Eur J Cell Biol. 2006 Feb;85(2):117-32 [16439309.001]
  • [Cites] Biochimie. 2006 Mar-Apr;88(3-4):387-97 [16480812.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] Nature. 2007 Mar 29;446(7135):562-6 [17392787.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7765-72 [17699781.001]
  • [Cites] Science. 2007 Dec 21;318(5858):1917-20 [18029452.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):4375-86 [18006504.001]
  • [Cites] Exp Cell Res. 2008 Oct 1;314(16):2999-3006 [18692045.001]
  • (PMID = 23656719.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA033505; United States / NCI NIH HHS / CA / R01 CA033505; United States / NCI NIH HHS / CA / R01 CA152870; United States / NCI NIH HHS / CA / R01 CA152870; United States / NCI NIH HHS / CA / U54 CA143876
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 6-formylindolo(3,2-b)carbazole; 0 / Carbazoles; 0 / Ligands; 0 / Receptors, Aryl Hydrocarbon; 5688UTC01R / Tretinoin; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC3693992
  •  go-up   go-down


6. Wallace AS, Supnick HT, Bunaciu RP, Yen A: RRD-251 enhances all-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells. Oncotarget; 2016 07 19;7(29):46401-46418
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RRD-251 enhances all-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells.
  • All-trans-retinoic acid (RA) is known to induce terminal granulocytic differentiation and cell cycle arrest of HL-60 cells.


7. Salem DA, Abd El-Aziz SM: Flowcytometric immunophenotypic profile of acute leukemia: mansoura experience. Indian J Hematol Blood Transfus; 2012 Jun;28(2):89-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flowcytometric immunophenotypic profile of acute leukemia: mansoura experience.
  • Acute leukemia (AL) displays characteristic patterns of antigen expression, which facilitate their identification and proper classification.
  • The purpose of this study is to evaluate the diagnostic usefulness of commonly used immune-markers for immunophenotyping of AL and to define the best immune-markers to be used for proper diagnosis and classification of AL.
  • We retrospectively analyzed the immunophenotypic data of 164 de novo AL patients from our institution during 2009 and 2010.
  • Among these patients, 68.9% were classified as acute myeloblastic leukemia (AML) while 31.1% classified as acute lymphoblastic leukemia (ALL).
  • The commonest FAB subtype in AML group was AML-M4/5 (34.5%) which may differ from most published data.
  • It was found that combined use of HLADR and CD34 was much more helpful in distinguishing APL from non-APL AML than either of these antigens alone.
  • Our analysis of AL phenotypes proved that employed antibody panels are adequate for proper diagnosis and classification of AL.
  • Flowcytometry was found to be especially useful in the identification of AML-M0 and differentiation of APL from non-APL AML.
  • Immunophenotyping results and FAB classification of our AL patients were comparable to internationally published studies apart from predominance of AML-M4/5 and more frequent APL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23730015.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3332273
  • [Keywords] NOTNLM ; Acute leukemia / Blood Transfusion Medicine / Flowcytometry / Hematology / Human Genetics / Immunophenotyping / Medicine & Public Health / Oncology
  •  go-up   go-down


8. Dai HP, Xue YQ, Wu LL, Pan JL, Gong YL, Wu YF, Zhang J, Wu DP, Chen SN: p210 BCR/ABL1 as a secondary change in a patient with acute myelomonocytic leukemia (M4Eo) with inv(16). Int J Hematol; 2012 Dec;96(6):814-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p210 BCR/ABL1 as a secondary change in a patient with acute myelomonocytic leukemia (M4Eo) with inv(16).
  • t(9;22) as a secondary change of inv(16) is a rare chromosome aberration in de novo acute myeloid leukemia (AML).
  • Here, we report the case of a 31-year-old man with this rare abnormality.
  • CBFB/MYH11 (A type) and BCR/ABL1 (b3a2) fusion transcripts were both detected by real-time quantitative RT-PCR.
  • The patient was treated with standard AML chemotherapy and autologous peripheral blood stem cell transplantation.
  • Molecular remission was achieved at the beginning of the third chemotherapy and he remained in remission until the last follow-up (22 months after diagnosis).
  • To our knowledge, this is the first reported case of de novo AML in which has p210(BCR/ABL1) occurred as a secondary change of inv(16).
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 16 / genetics. Fusion Proteins, bcr-abl / genetics. Leukemia, Myelomonocytic, Acute / genetics

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] Int J Hematol. 2011 Jun;93(6):806-10 [21523337.001]
  • [Cites] Leuk Lymphoma. 2002 May;43(5):1137-40 [12148898.001]
  • [Cites] Cancer Genet Cytogenet. 2010 Jul 1;200(1):54-9 [20513535.001]
  • [Cites] Blood. 1998 Jul 15;92(2):574-88 [9657758.001]
  • [Cites] Br J Haematol. 2011 Mar;152(6):713-20 [21275954.001]
  • [Cites] Leukemia. 2001 Apr;15(4):695 [11368385.001]
  • [Cites] Leuk Lymphoma. 2011 Mar;52(3):531-5 [21281226.001]
  • [Cites] Br J Haematol. 1994 May;87(1):51-6 [7524618.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jan;58(1):29-34 [1728947.001]
  • [Cites] Br J Haematol. 1988 Aug;69(4):576 [3165674.001]
  • [Cites] Am J Clin Pathol. 2006 Feb;125(2):260-6 [16393682.001]
  • [Cites] Am J Hematol. 1994 Jan;45(1):94-6 [8250017.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Hematol Oncol Clin North Am. 2009 Aug;23(4):633-54 [19577162.001]
  • [Cites] Br J Haematol. 1992 Nov;82(3):623-6 [1486046.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):873-5 [9722319.001]
  • [Cites] Leuk Res. 2004 Jan;28(1):97-9 [14630086.001]
  • (PMID = 23054652.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzamides; 0 / CBFbeta-MYH11 fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 04079A1RDZ / Cytarabine; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; ZRP63D75JW / Idarubicin
  •  go-up   go-down


9. Lulli V, Romania P, Riccioni R, Boe A, Lo-Coco F, Testa U, Marziali G: Transcriptional silencing of the ETS1 oncogene contributes to human granulocytic differentiation. Haematologica; 2010 Oct;95(10):1633-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional silencing of the ETS1 oncogene contributes to human granulocytic differentiation.
  • This study focuses on the role of Ets-1 during granulocytic differentiation of NB4 promyelocytic and HL60 myeloblastic leukemia cell lines induced by all-trans retinoic acid.
  • Expression of Ets-1 was also reduced during dimethylsulfoxide-induced differentiation and during granulocytic differentiation of human CD34(+) hematopoietic progenitor cells but not in NB4.R2 and HL60R cells resistant to all-trans retinoic acid.
  • In line with these observations, transduction of a transdominant negative molecule of Ets-1, which inhibited DNA binding and transcriptional activity of the wild-type Ets-1, significantly increased chemical-induced differentiation.
  • Interestingly, p51 Ets-1 over-expression was frequently observed in CD34(+) hematopoietic progenitor cells derived from patients with acute myeloid leukemia, as compared to its expression in normal CD34(+) cells.
  • CONCLUSIONS: Our results indicated that a decreased expression of Ets-1 protein generalizes to granulocytic differentiation and may represent a crucial event for granulocytic maturation.
  • [MeSH-minor] Cell Line, Tumor. HL-60 Cells. Hematopoietic Stem Cells / cytology. Hematopoietic Stem Cells / drug effects. Humans. Leukemia / pathology. Leukemia, Promyelocytic, Acute. RNA, Small Interfering / pharmacology


10. Reiterer G, Chen L, Tassef R, Varner JD, Chen CY, Yen A: RAF associates with phosphorylated nuclear BubR1 during endoreduplication induced by JAK inhibition. Cell Cycle; 2010 Aug 15;9(16):3297-304
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of JAK signaling in cell cycle transit and maintenance of genomic stability was determined in HL-60 human myeloblastic leukemia cells.
  • In the current study we find that JAK inhibition caused nuclear re-localization of RAF-1 which could be inhibited by RAF inhibitor GW5074.
  • In this hypothetical model JAK suppresses RAF/MEK phosphorylation and nuclear re-localization, but JAK inhibition induces the phosphorylations and relocalization with association of RAF and phosphorylated BubR1 in the nucleus leading to endoreduplication.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2001 Jun 25;153(7):1355-67 [11425867.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3639-52 [16046481.001]
  • [Cites] Cell Mol Life Sci. 2005 Nov;62(21):2438-59 [16143828.001]
  • [Cites] J Neurochem. 2006 May;97(4):957-67 [16686690.001]
  • [Cites] Mol Cell. 2006 Aug;23(4):561-74 [16916643.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9083-9 [16982750.001]
  • [Cites] J Biol Chem. 2007 May 18;282(20):15217-27 [17376779.001]
  • [Cites] Cell Prolif. 2007 Jun;40(3):397-410 [17531083.001]
  • [Cites] Mol Pharmacol. 2008 Feb;73(2):419-30 [17991869.001]
  • [Cites] Exp Cell Res. 2009 Aug 1;315(13):2241-8 [19298812.001]
  • [Cites] EMBO J. 2009 Jul 22;28(14):2077-89 [19407811.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1278-85 [14576056.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1463-7 [7811320.001]
  • [Cites] Trends Biochem Sci. 1994 Nov;19(11):470-3 [7855889.001]
  • [Cites] Science. 1995 Sep 22;269(5231):1721-3 [7569900.001]
  • [Cites] J Biol Chem. 1995 Nov 10;270(45):26742-5 [7592906.001]
  • [Cites] Cell. 1996 Mar 22;84(6):889-97 [8601312.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11107-12 [9736697.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):7487-98 [9819434.001]
  • [Cites] Oncogene. 1998 Dec 17;17(24):3157-67 [9872331.001]
  • [Cites] J Cell Sci. 2001 Dec;114(Pt 24):4385-95 [11792804.001]
  • [Cites] Blood. 2003 Apr 15;101(8):2940-54 [12480704.001]
  • [Cites] Mol Endocrinol. 1999 Apr;13(4):555-65 [10194762.001]
  • [Cites] Genome Biol. 2004;5(12):253 [15575979.001]
  • [Cites] Curr Protein Pept Sci. 2004 Dec;5(6):475-85 [15581417.001]
  • [Cites] Mol Cell Biol. 2005 May;25(10):4046-61 [15870277.001]
  • [Cites] Hum Mol Genet. 2001 Aug 15;10(17):1741-52 [11532983.001]
  • (PMID = 20703093.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA033505; United States / NCI NIH HHS / CA / R01 CA100498; United States / NCI NIH HHS / CA / CA100498; United States / NCI NIH HHS / CA / CA33505
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone; 0 / Indoles; 0 / Phenols; 0 / Protein Kinase Inhibitors; EC 2.7.10.2 / Janus Kinases; EC 2.7.11.1 / BUB1 protein, human; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 2.7.12.2 / MAP Kinase Kinase 1
  • [Other-IDs] NLM/ PMC3230478
  •  go-up   go-down






Advertisement